Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Chubb
Teva
Argus Health
Farmers Insurance
US Army
Cipla
Merck
AstraZeneca
Novartis

Generated: February 21, 2018

DrugPatentWatch Database Preview

Janssen Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for JANSSEN PHARMS, and when can generic versions of JANSSEN PHARMS drugs launch?

JANSSEN PHARMS has fifty-six approved drugs.

There are thirty-three US patents protecting JANSSEN PHARMS drugs and there have been four Paragraph IV challenges on JANSSEN PHARMS drugs in the past three years.

There are six hundred and forty-seven patent family members on JANSSEN PHARMS drugs in fifty-eight countries and sixty-six supplementary protection certificates in fifteen countries.

Summary for Janssen Pharms
International Patents:647
US Patents:33
Tradenames:55
Ingredients:34
NDAs:56

Drugs and US Patents for Janssen Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Janssen Pharms INVOKAMET XR canagliflozin; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 205879-004 Sep 20, 2016 RX Yes Yes 8,785,403 ➤ Sign Up Y ➤ Sign Up
Janssen Pharms CONCERTA methylphenidate hydrochloride TABLET, EXTENDED RELEASE;ORAL 021121-002 Aug 1, 2000 AB RX Yes No 6,930,129*PED ➤ Sign Up ➤ Sign Up
Janssen Pharms SPORANOX itraconazole SOLUTION;ORAL 020657-001 Feb 21, 1997 RX Yes Yes 6,407,079 ➤ Sign Up ➤ Sign Up
Janssen Pharms CONCERTA methylphenidate hydrochloride TABLET, EXTENDED RELEASE;ORAL 021121-004 Apr 1, 2002 AB RX Yes No 9,000,038*PED ➤ Sign Up ➤ Sign Up
Janssen Pharms RISPERDAL CONSTA risperidone INJECTABLE;INTRAMUSCULAR 021346-001 Oct 29, 2003 RX Yes Yes 6,194,006*PED ➤ Sign Up Y ➤ Sign Up
Janssen Pharms ORTHO-NOVUM 7/7/7-28 ethinyl estradiol; norethindrone TABLET;ORAL-28 018985-002 Apr 4, 1984 AB RX Yes Yes ➤ Sign Up ➤ Sign Up
Janssen Pharms INVOKANA canagliflozin TABLET;ORAL 204042-001 Mar 29, 2013 RX Yes No ➤ Sign Up ➤ Sign Up
Janssen Pharms RISPERDAL risperidone TABLET, ORALLY DISINTEGRATING;ORAL 021444-004 Dec 23, 2004 AB RX Yes No ➤ Sign Up ➤ Sign Up
Janssen Pharms ULTRACET acetaminophen; tramadol hydrochloride TABLET;ORAL 021123-001 Aug 15, 2001 AB RX Yes Yes ➤ Sign Up ➤ Sign Up
Janssen Pharms RISPERDAL CONSTA risperidone INJECTABLE;INTRAMUSCULAR 021346-001 Oct 29, 2003 RX Yes Yes 6,667,061*PED ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Janssen Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Janssen Pharms RAZADYNE galantamine hydrobromide TABLET;ORAL 021169-002 Feb 28, 2001 6,358,527 ➤ Sign Up
Janssen Pharms ULTRACET acetaminophen; tramadol hydrochloride TABLET;ORAL 021123-001 Aug 15, 2001 5,336,691 ➤ Sign Up
Janssen Pharms INVEGA SUSTENNA paliperidone palmitate SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 022264-003 Jul 31, 2009 5,254,556*PED ➤ Sign Up
Janssen Pharms TOPAMAX topiramate TABLET;ORAL 020505-002 Dec 24, 1996 6,503,884*PED ➤ Sign Up
Janssen Pharms CONCERTA methylphenidate hydrochloride TABLET, EXTENDED RELEASE;ORAL 021121-004 Apr 1, 2002 8,629,179*PED ➤ Sign Up
Janssen Pharms VERMOX mebendazole TABLET, CHEWABLE;ORAL 017481-001 Approved Prior to Jan 1, 1982 3,657,267 ➤ Sign Up
Janssen Pharms TOPAMAX topiramate TABLET;ORAL 020505-004 Dec 24, 1996 5,998,380*PED ➤ Sign Up
Janssen Pharms CONCERTA methylphenidate hydrochloride TABLET, EXTENDED RELEASE;ORAL 021121-001 Aug 1, 2000 9,000,038*PED ➤ Sign Up
Janssen Pharms FLOXIN ofloxacin TABLET;ORAL 019735-003 Dec 28, 1990 4,382,892 ➤ Sign Up
Janssen Pharms ORTHO TRI-CYCLEN ethinyl estradiol; norgestimate TABLET;ORAL-21 019697-002 Jul 3, 1992 4,544,554 ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for JANSSEN PHARMS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Extended-release Injectable Suspension 39 mg/0.25 mL,78 mg/0.5 mL,117 mg/0.75 mL,156 mg/mL and234 mg/1.5 mL ➤ Subscribe 11/21/2017
➤ Subscribe Tablets 100 mg and 300 mg ➤ Subscribe 3/29/2017
➤ Subscribe Tablets 50 mg/500 mg, 50mg/1000 mg, 150mg/500 mg, and150 mg/1000 mg ➤ Subscribe 3/29/2017
➤ Subscribe Tablets 10 mg, 15 mg, and 20 mg ➤ Subscribe 7/1/2015
➤ Subscribe Oral Solution 10 mg/mL ➤ Subscribe 5/3/2013
➤ Subscribe Oral Solution 25 mg/mL ➤ Subscribe 7/30/2009
➤ Subscribe Transdermal System 0.15 mg/0.02 mg per 24 hours ➤ Subscribe 3/22/2007
➤ Subscribe Extended-release Capsules 16 mg and 24 mg ➤ Subscribe 3/11/2006
➤ Subscribe Extended-release Capsules 8 mg ➤ Subscribe 3/2/2006
➤ Subscribe Tablets 6.25 mg and 12.5 mg ➤ Subscribe 12/8/2005
➤ Subscribe Tablets 50 mg ➤ Subscribe 9/8/2005
➤ Subscribe Capsules 15 mg and 25 mg ➤ Subscribe 9/7/2005
➤ Subscribe Extended-release Tablets 18 mg*, 27 mg, 36 mg and 54 mg ➤ Subscribe 7/19/2005
➤ Subscribe Extended-release Tablets 18 mg, 27 mg, 36 mg and 54 mg ➤ Subscribe 7/19/2005
➤ Subscribe Orally Disintegrating Tablets 0.25 mg ➤ Subscribe 4/11/2005
➤ Subscribe Orally Disintegrating Tablets 3 mg and 4 mg ➤ Subscribe 3/23/2005
➤ Subscribe Tablets 4 mg, 8 mg and 12 mg ➤ Subscribe 2/28/2005
➤ Subscribe Tablets 25 mg, 100 mg and 200 mg ➤ Subscribe 12/26/2001

Non-Orange Book US Patents for Janssen Pharms

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,034,101 United States Patent: 6034101   ( 1 ➤ Sign Up
7,521,430 N-glucoside compounds having an inhibitory activity against sodium-dependent glucose transporter ➤ Sign Up
7,084,124 Substituted indazole-O-glucosides ➤ Sign Up
6,809,107 Neurotrophic pyrrolidines and piperidines, and related compositions and methods ➤ Sign Up
7,799,345 Preparation of injectable suspensions having improved injectability ➤ Sign Up
8,822,458 Substituted oxazolidinones and their use in the field of blood coagulation ➤ Sign Up
7,482,330 Substituted fused heterocyclic C-glycosides ➤ Sign Up
8,246,950 Stable digestive enzyme compositions ➤ Sign Up
7,094,763 Substituted fused heterocyclic C-glycosides ➤ Sign Up
8,936,810 Methods and apparatus for determining formulation orientation of multi-layered pharmaceutical dosage forms ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Janssen Pharms Drugs

Supplementary Protection Certificates for Janssen Pharms Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0653 Netherlands ➤ Sign Up PRODUCT NAME: FENTANYL IN ELKE DOOR HET BASISOCTROOI BESCHERMDE VERSCHIJNINGSVORM; REGISTRATION NO/DATE: EU/1/10/644/001-004 20100906
2015000093 Germany ➤ Sign Up PRODUCT NAME: LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 87675.00.00 20150720; FIRST REGISTRATION: SLOWAKEI 17/0017/15-S 20150129
00140 Netherlands ➤ Sign Up PRODUCT NAME: GALANTAMINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZUURADDITIEZOUT, IN HET BIJZONDER GALANTAMINE HYDROBROMIDE; NAT. REGISTRATION NO/DATE: RVG 29073 - RVG 29076 20030702; FIRST REGISTRATION: SE 15561 - 15565 20000225
2014000024 Germany ➤ Sign Up PRODUCT NAME: FENTANYL IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: EU/1/10/644/001-004 20100831
1214076/01 Switzerland ➤ Sign Up PRODUCT NAME: DROSPIRENONE + ETHINYLESTRADIOL; REGISTRATION NUMBER/DATE: SWISSMEDIC 57946 13.06.2008
C0051 France ➤ Sign Up PRODUCT NAME: RIVAROXABAN; REGISTRATION NO/DATE: EU/1/08/472/001-008 20080930
C0034 France ➤ Sign Up PRODUCT NAME: CANAGLIFLOZINE; REGISTRATION NO/DATE: EU/1/13/884/001-008 20131115
2014000050 Germany ➤ Sign Up PRODUCT NAME: CANAGLIFLOZIN; REGISTRATION NO/DATE: EU/1 /13/884/001-008 20131115
11/021 Ireland ➤ Sign Up PRODUCT NAME: PALIPERIDONE PALMITATE ESTER; REGISTRATION NO/DATE: EU/1/11/672/001-006 20110304
2014008,C1651658 Lithuania ➤ Sign Up PRODUCT NAME: CANAGLIFOZINUM; REGISTRATION NO/DATE: EU/1/13/884/001 - EU/1/13/884/004, 2013- 11-15 EU/1/13/884/005 - EU/1/13/884/008 20131115
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Moodys
McKesson
Teva
Fish and Richardson
US Department of Justice
Mallinckrodt
Citi
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot